Trujillo Focuses on Alzheimer's Disease Treatment with TruCytonics
Can Alzheimer’s disease be treated – or even cured – with the use of radio frequency radiations?
That is the question Dr. Roberto Trujillo seeks to answer with his new company, TruCytonics.
Trujillo has been a presence around the Johns Hopkins University Montgomery County Campus for years, having taught in the biotechnology master’s program and running his biotechnology company, TruBios, from a leased office on campus. An outgrowth of TruBios is his company CerCa Solutions, which developed a minimally invasive device that uses photodynamic therapy to diagnose and treat cervical cancer. Trujillo has focused his attention on his native Latin American region.
Now, he is focusing on TruCytonics, a new company he launched in January. TruCytonics uses a medical device called a Cytotron as its foundation. (Cytonics is the electronics of living cells.)
The Cytotron is akin to an MRI machine: Patients enter the tube-like machine while lying motionless on a flatbed. But whereas an MRI is a diagnostic device used to determine what’s wrong with a patient, the Cytotron is a therapeutic device used to treat the patient. It was invented by Dr. Rajah Vijay Kumar of India, who uses it to treat cancer and arthritis.
The Cytotron is based on Rotational Field Quantum Magnetic Resonance – RFQMR – Technology, which uses electromagnetic beams in the radio frequency spectrum. The beams are targeted to tissues to stop cancer tumor growth and to stimulate cartilage growth.
Trujillo and Kumar teamed up and believe the Cytotron has the potential to treat Alzheimer’s disease, a huge and growing health concern in the United States, where more than 5.5 million people suffer from the neurodegenerative disease. That number is expected to triple by 2050. Alzheimer’s disease is one of the leading causes of death in the United States, and costs the country hundreds of billions of dollars annually in health care costs.
To treat Alzheimer’s disease patients, patients would enter the Cytotron. The Cytotron would send a radio frequency to activate specific proteins that could regrow brain cells and boost the electrical charges of the degenerate cells back to healthy levels. Patients would likely need to be treated for one hour a day for 28 days. The treatment is considered non-invasive.
Using the Cytotron in this way is a form of personalized medicine, with the frequency levels and location destinations adjusted and targeted to each patient’s needs.
Trujillo is seeking approval of the U.S. Food and Drug Administration to use the technology to treat Alzheimer’s disease. He is preparing to start Stage 2 clinical trials; Stage 1 trials were successfully completed in India.
In the future, Trujillo thinks the device could be used to treat stroke, Parkinson’s disease, cerebral palsy, amyotrophic lateral sclerosis (ALS) and other degenerative diseases.
“If our science can be translated to helping people, it’s worth it,” Trujillo said. “What we do here are the solutions of tomorrow.”